The estimated Net Worth of Pravin Dugel is at least $33.6 Million dollars as of 23 August 2024. Dr Dugel owns over 20,880 units of IVERIC bio Inc stock worth over $32,458,296 and over the last 6 years he sold ISEE stock worth over $313,552. In addition, he makes $780,650 as Pres at IVERIC bio Inc.
Dr has made over 12 trades of the IVERIC bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,880 units of ISEE stock worth $188,338 on 23 August 2024.
The largest trade he's ever made was exercising 70,000 units of IVERIC bio Inc stock on 1 April 2021 worth over $2,796,500. On average, Dr trades about 10,954 units every 50 days since 2018. As of 23 August 2024 he still owns at least 812,473 units of IVERIC bio Inc stock.
You can see the complete history of Dr Dugel stock trades at the bottom of the page.
Dr. Pravin U. Dugel M.D. is the Pres at IVERIC bio Inc.
As the Pres of IVERIC bio Inc, the total compensation of Dr D at IVERIC bio Inc is $780,650. There are 6 executives at IVERIC bio Inc getting paid more, with Glenn Sblendorio having the highest compensation of $2,462,150.
Dr D is 57, he's been the Pres of IVERIC bio Inc since . There are 6 older and 8 younger executives at IVERIC bio Inc. The oldest executive at IVERIC bio Inc is Calvin Roberts, 67, who is the Independent Director.
Pravin's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver..., and Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
IVERIC bio Inc executives and other stock owners filed with the SEC include: